Amendments to the Claims:

Please amend claims 1, 2, 4, 18 and 19. These amendments introduce no new matter and support for the amendment is replete throughout the specification and claims as originally filed. These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter, or agreement with any objection or rejection of record.

Please cancel claims 3, 9 and 14. Cancellation of these claims is without prejudice, without intent to abandon any originally-claimed subject matter, and without intent to acquiesce in any rejection of record. Applicant expressly reserves the right to file one or more continuing applications containing these cancelled claims.

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A method of identifying a new composition with a desired activity, the method comprising:

providing a first set of compositions capable of causing a first demonstrated therapeutic activity, wherein at least one member of the first set of compositions is capable of causing ~~comprises at least a first demonstrated activity and~~ a second desired activity related to a different disease area of interest;

determining a genetic response profile for each member composition of the first set of compositions by a) providing a plurality of cell lines, wherein the plurality of cell lines comprises at least one modified cell line which differs from a corresponding parent cell line ~~in either the first demonstrated activity or the second desired activity~~ in at least one selected protein or nucleic acid; b) treating each member of the plurality of cell lines with each member composition of the first set of compositions; and c) detecting an activity or concentration of the selected protein or nucleic acid in ~~one or more~~ responses ~~to~~ the member compositions;

~~comparing~~ correlating the one or more responses from the genetic response profile to the first demonstrated therapeutic activity and second desired activity caused by ~~of~~ each member composition, thereby identifying a pattern of responses correlating to a decrease in the first demonstrated therapeutic activity and an increase in the second desired activity; and

screening a second set of compositions for the pattern of responses, thereby identifying a new composition capable of causing ~~with~~ the second desired activity.

2. (Currently amended) The method of claim 1, wherein the modified cell line differs from the corresponding parent cell line in the activity or concentration of ~~a~~ the selected protein or nucleic acid.

3. (Cancelled)

4. (Currently amended) The method of ~~claim 3~~ claim 1, wherein the modified cell line is generated by treating the corresponding parental cell line with one or more agents ~~comprise compositions~~ that modify DNA structure, alter DNA activity, alter protein expression, inhibit protein functional activity, induce protein functional activity, or combinations thereof.

5. (Original) The method of claim 4, wherein the compositions that alter DNA activity or alter protein expression comprise transcription inducers, transcription inhibitors, translation inducers, translation inhibitors, compositions that alter post-transcription modification, compositions that alter splicing, or compositions that alter transportation.

6. (Withdrawn) The method of claim 4, wherein the one or more agents comprise one or more antisense agents, ribozymes, protein ligands, growth factors, antibodies, antigens, antibiotics, transcription inhibitors, transcription enhancers, translation inhibitors, or translation enhancers.

7. (Original) The method of claim 1, wherein providing the plurality of cell lines comprises performing a genetic selection.

8. (Original) The method of claim 1, wherein the at least one modified cell line comprises a cell line that is drug resistant.

9. (Cancelled)

10. (Original) The method of claim 1, wherein the second desired activity comprises an antiproliferative activity.

11. (Original) The method of claim 1, wherein the second desired activity comprises an anti-neoplastic activity.

12. (Original) The method of claim 1, wherein the first or second set of compositions comprises between about 5 and about 50 compositions.

13. (Original) The method of claim 1, wherein the first or second set of compositions comprises between about 10 and about 20 compositions.

14. (Cancelled)

15. (Original) The method of claim 1, wherein providing the plurality of cell lines comprises providing cell lines derived from different types of tissues or tumors, primary cell lines, genetically-modified cell lines, or combinations thereof.

16. (Original) The method of claim 1, wherein providing the plurality of cell lines comprises providing target-specific modified cell lines and parent cell lines.

17. (Original) The method of claim 1, wherein the plurality of cell lines comprises about two to about ten cell lines.

18. (Currently Amended) The method of claim 1, wherein the plurality of cell lines comprises cell lines relevant to the analysis of ~~a particular~~ the different disease area of interest.

19. (Currently amended) The method of claim 18, wherein the ~~particular~~ disease area of interest comprises cancer, inflammation, cardiovascular disease, diabetes, an infectious disease, a proliferative disease, an immune system disorder, or a central nervous system disorder.

20. (Original) The method of claim 1, wherein one or more cell lines of the plurality of cell lines are selected from the group consisting of: PC3, DU145, LNCaP, MDA-PCa 2a, MDA-PCa 2b, ARCaP, 293, 293Tet-Off, CHO-AA8 Tet-Off, MCF7, MCF7 Tet-Off, LNCap, T-5, BSC-1, BHK-21, Phinx-A, 3T3, HeLa, PC3, DU145, ZR 75-1, HS 578-T, DBT, Bos, CV1, L-2, RK13, HTTA, HepG2, BHK-Jurkat, Daudi, RAMOS, KG-1, K562, U937, HSB-2, HL-60, MDAHB231, C2C12, HTB-26, HTB-129, HPIC5, A-431, CRL-1573, 3T3L1, Cama-1, J774A.1, HeLa 229, PT-67, Cos7, OST7, HeLa-S, THP-1, and NXA.

21. (Original) The method of claim 1, wherein treating each member of the plurality of cell lines comprises administering varying concentrations of the plurality of compounds, thereby generating a dose-response.

22. (Original) The method of claim 1, wherein detecting the one or more responses comprises performing one or more broad scanning techniques and measuring the concentration or activity of at least one gene or gene product in the plurality of cell lines.

23. (Original) The method of claim 22, wherein the gene product comprises RNA and the one or more broad scanning techniques comprise microarray analysis, differential display, EST screening, or combinations thereof.

24. (Withdrawn) The method of claim 22, wherein the gene product comprises protein and the one or more broad scanning techniques comprise 2D-gel electrophoresis, LC mass spectrometry, immunoscreening techniques, or combinations thereof.

25. (Withdrawn) The method of claim 1, wherein detecting the one or more responses comprises detecting a change in cellular transcriptional activity, cellular translational

activity, gene product activity, stability, abundance, compartmentalization, phenotypic endpoint or a combination thereof.

26. (Withdrawn) The method of claim 1, wherein detecting the one or more responses comprises performing an RNA transcription assay, a protein expression assay, a binding assay, a protein function assay, a phenotype-based cellular assay, a metabolic assay, a small molecule assay, an ionic flux assay, a reporter gene assay, a cell proliferation assay, an apoptosis assay, a cell adhesion assay, a cell invasion assay , a calcium signaling assay, a cell cycling assay, a nitric oxide signaling assay, a receptor expression assay, a gene promoter reporter assay, or a combination thereof.

27. (Withdrawn) The method of claim 22, wherein the gene product comprises one or more proteins selected from the group: signaling proteins, regulatory proteins, pathway specific proteins, and receptor proteins.

28. (Withdrawn) The method of claim 1, wherein detecting the one or more responses comprises performing flow cytometry.

29. (Withdrawn) The method of claim 1, wherein detecting the one or more responses comprises performing mass spectrometry.

30. (Original) The method of claim 1, wherein comparing the one or more responses comprises performing a comparative analysis on the one or more responses, the first demonstrated activity and the second desired activity.

31. (Original) The method of claim 30, wherein performing a comparative analysis comprises generating a graphical representation of the one or more responses over a plurality of time points.

32. (Original) The method of claim 30, wherein performing a comparative analysis comprises performing one or more techniques selected from the group consisting of: clustering analysis, multivariate analysis, analysis in n-dimensional space, principle component analysis, and difference analysis.

33. (Original) The method of claim 1, wherein screening the second set of compositions comprises screening a library of compositions.

34. (Original) The method of claim 1, wherein screening the second set of compositions comprises determining a genetic response profile for one or more members of the library of test compositions by:

treating each member of the plurality of cell lines with a member composition of the library of test compositions; and

detecting one or more responses to the member composition.

35. (Original) The method of claim 34, wherein the one or more responses collected for the genetic response profiles of the second set of compositions comprises a subset of the responses collected for the genetic response profiles of the first set of compositions.

36. (Cancelled)

37. (Withdrawn) The method of claim 1, wherein the first or second set of compositions comprises one or more research chemicals.

38. (Withdrawn) The method of claim 1, wherein the first or second set of compositions comprises one or more libraries of synthetic compositions.

39. (Withdrawn) The method of claim 1, wherein the first or second set of compositions comprises one or more or herbal compositions.